| Document |
Document Title |
|
WO/2010/151006A1 |
Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same. Since the organic electroluminescent compound disclosed herein exhibits good luminescence efficiency and excellent life pro...
|
|
WO/2010/150281A2 |
The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The ...
|
|
WO/2010/144640A2 |
The present invention provides processes for the stereoselective synthesis of 6-alpha-amino morphinans. In particular, the invention provides processes for the reductive amination of 6-keto normorphinans by catalytic transfer hydrogenation.
|
|
WO/2010/133569A1 |
The invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norep...
|
|
WO/2010/130672A1 |
The invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norep...
|
|
WO/2010/132524A1 |
Compounds containing 2-azatriphenylene are provided. In particular, compounds containing a 2-azatriphenylene core having an additional aromatic group are provided. The compounds provided may be emissive or non-emissive materials. The com...
|
|
WO/2010/129055A1 |
The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical compositio...
|
|
WO/2010/125033A1 |
The invention relates to compounds of formula (I), processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norep...
|
|
WO/2010/116142A2 |
The invention provides fluorophores of formulae (I) and (II) and also fluorescent sensor compounds comprising fluorophore moieties based on such fluorophores in combination with a receptor moiety. There is further provided a method of se...
|
|
WO/2010/114958A1 |
The present invention relates to Bridged Bicyclic Heterocycle Derivatives, compositions comprising a Bridged Bicyclic Heterocycle Derivative, and methods of using the Bridged Bicyclic Heterocycle Derivatives for treating or preventing ob...
|
|
WO2010110380A1 |
Disclosed is a compound having an activity of promoting the production of a low-molecular-weight EPO and/or an activity of promoting the production of hemoglobin. Specifically disclosed is a fused piperidine compound represented by gener...
|
|
WO/2010/092771A1 |
Nitrogen-containing compounds represented by general formula (I1) or salts thereof; and insecticides, miticides, sanitary harmful insect expellants, or harmful organism control agents, which contain the compounds or salts thereof as the ...
|
|
WO/2010/089510A2 |
The invention relates to a compound of the general formula (I) in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, NR8R9 group; m, n, o and p are independently an integer equal to 0,...
|
|
WO/2010/083436A1 |
The present invention provides compounds of formula I: formula (I) wherein X1- X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated ...
|
|
WO/2010/078421A1 |
The present invention relates to substituted 5,6-dihydro-6- phenylbenzo[f]isoquinolin-2-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted...
|
|
WO/2010/065441A1 |
The present disclosure generally relates to a process for converting a fused, tricyclic compound to a fused, tetracyclic compound that includes a furan ring therein. More particularly, the present disclosure related to a process for prep...
|
|
WO/2010/063638A1 |
The present invention concerns novel compounds having the structure (I). Another object of the invention is the use of compounds (I) for the fabrication of a medicament which is used for the treatment of tumour diseases.
|
|
WO/2010/061625A1 |
A compound represented by general formula (1). Thus, a novel compound, which shows practically sufficient light-emitting properties not only as a light-emitting dopant but also in the case where the compound is used alone, and utilizati...
|
|
WO/2010/062245A1 |
Disclosed herein is at least one spirocyclobutyl piperidine derivative with formula I, or pharmaceutically acceptable salts of formula I, or mixtures thereof: wherein A is at least one pharmaceutical composition comprising at least one s...
|
|
WO/2010/056066A1 |
Provided are an electroluminescent compound and an electroluminescent device comprising the same as a host material: When used as a host material of an electroluminescent material in an OLED device, the disclosed electroluminescent compo...
|
|
WO/2010/051048A1 |
The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule...
|
|
WO/2010/049146A1 |
The present invention relates to substituted spiroamines, having the general formula (I), processes for the preparation thereof, medicaments containing these compounds and the use of substituted spiroamines for the preparation of medicam...
|
|
WO/2010/050781A1 |
Disclosed Provided are a novel organic electroluminescent compound and an organic electroluminescent device using the same as an electroluminescent material. The disclosed organic electroluminescent compound is represented by Chemical Fo...
|
|
WO/2010/047318A1 |
Disclosed are novel helicene derivative, axially asymmetric amino acid, amine or aminoalcohol derivative, and azaperylene derivative. The inventors have created compounds each represented by general formula (I), (I'), (II), (II') or (III...
|
|
WO/2010/045258A2 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I'A or I'B, where the definitions of the variables are provided herein. The pres...
|
|
WO/2010/044981A2 |
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2010/041748A1 |
Disclosed is a prophylactic or therapeutic agent for diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cer...
|
|
WO/2010/028542A1 |
The present invention in the field of pharmaceutical chemistry provides a type of pleuromutilin phosphate according to formula (I), its pharmaceutical composition, its preparation method and uses thereof. The pleuromutilin phosphate of t...
|
|
WO/2010/026771A1 |
A nitrogenated heterocyclic compound represented by formula (I) [wherein X represents a C1-12 alkyl group which may have a substituent, or the like, and m represents an integer of 0 to 6, provided that, when m represents an integer of 2 ...
|
|
WO/2010/026989A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by general formula (1) [wherein A represents –C(R7)(R8)- or –N(R9)-; W represents an oxygen atom or a sulfur atom; n represents...
|
|
WO/2010/021149A1 |
Disclosed is a novel prophylactic/therapeutic agent for digestive system diseases. The prophylactic/therapeutic agent for digestive system diseases comprises a compound represented by the formula or a salt or prodrug thereof. In the form...
|
|
WO/2010/018842A1 |
Disclosed is a benzofluoranthene derivative represented by formula (1) [wherein at least one pair of "R1 and R2" and "R3 and R4" are linked to each other to form a ring represented by formula (2)].
|
|
WO/2010/011619A1 |
8-Substituted-2,6-methano-3-benzazocines of general structure (I) are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
|
|
WO/2010/007794A1 |
Disclosed is a novel compound useful as a prophylactic and/or therapeutic agent for diabetes, insulin resistance, diabetic complications, obesity, dyslipidemia, hypertension, fatty liver or metabolic syndrome. Specifically disclosed is ...
|
|
WO/2010/007756A1 |
The object aims to provide an effective inhibitor of TTK protein kinase and an effective anti-cancer agent. The object can be achieved by a compound of the invention and inventions related to the compound (e.g., a pharmaceutical composi...
|
|
WO/2009/152577A1 |
The present invention relates to a process for the preparation of an N-demethyl morphinane or a protected form thereof. In one form the preparation of the N-demethyl morphinane or a protected form thereof involves the N-demethylation of ...
|
|
WO/2009/146288A1 |
The invention generally provides processes and intermediate compounds useful for the production of normorphinans and derivatives of normorphinans,eg.
|
|
WO/2009/141387A1 |
Compounds of the general formula (I) and compounds of the general formula (II), use of compounds (I) or (II) as visible or invisible marking materials, for coloring of materials, in laser welding of materials, for identification of bases...
|
|
WO/2009/138386A2 |
The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxy...
|
|
WO/2009/120774A2 |
The present invention is related to the synthesis of huperzine A. The synthesis includes a variety of process steps that increase productivity, reduce safety concerns, and allow for increasing production of compounds of desired optical i...
|
|
WO/2009/118382A1 |
The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization and their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of Formula (I) wherein R1, R2, R...
|
|
WO/2009/119086A1 |
Disclosed is a method for commercially producing a 9-hydroxymethyl-cyclohepta[b]pyridine-3-carboxylate ester derivative. Specifically disclosed is a method for producing a 9-hydroxymethyl-cyclohepta[b]pyridine-3-carboxylate ester derivat...
|
|
WO/2009/111337A1 |
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 an...
|
|
WO/2009/108332A1 |
This invention relates to novel compounds of the Formulae I or II and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modul...
|
|
WO/2009/107389A1 |
Disclosed are a novel compound functioning as an LXR antagonist and a pharmaceutical product containing the compound. Specifically disclosed is a tricyclic compound represented by general formula (1), a pharmacologically acceptable salt ...
|
|
WO/2009/100872A1 |
The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxys...
|
|
WO/2009/095376A1 |
The invention relates to the use of derivatives of 1,8-naphthalimide and of salts thereof as scintillation agents and, more precisely, as agents for discriminating between fast neutrons and gamma rays. It also relates to liquid scintilla...
|
|
WO/2009/093433A1 |
Disclosed is a novel anthrapyridone compound represented by formula (1) or a salt thereof. The compound or a salt thereof enables formation of a magenta dye having a hue with high definition suitable for inkjet recording and excellent st...
|
|
WO/2009/086416A1 |
The invention is directed to use of hedgehog inhibitors in conjunction with chemotherapy in treating cancers, and preventing relapses thereby.
|
|
WO/2009/080198A1 |
The invention relates to novel substituted fused cyanopyridine derivatives of formula (I), wherein the ring Q represents a group of formula (a), (b), (c), (d), (e), (f), (g) or (h), * representing the point of attachment to the C2 atom, ...
|
